CAMP4 Therapeutics 3rd Annual Guggenheim Healthcare Innovation Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Innovation Conference here in Boston. I'm Delma Kayate and I'm a research analyst here at Guggenheim. It's my pleasure to welcome Josh Mandel-Brehm, the Chief Executive Officer from CAMP4 Therapeutics. It's a pleasure to have you here, Josh. Maybe, it's an exciting moment for the company because you are moving into the clinic and you expect the first patients to be dosed by the end of the year. But before jumping into the Q&A session, why don't you give us an overview of the different programs you're running, where you stand, and the key milestones that we should expect over the next 12 months or so?
Yeah, absolutely. Thank you for inviting us here. We appreciate it. Good pronunciation of the name. Most people Oh. don't get it right.
You got it right. I was really afraid of that.
No, you did good. That was good. So maybe just to take a step back. CAMP4 is using antisense oligonucleotides to increase gene expression. So you can think of us as the inverse of the Ionis and the Alnylam of the world, which is really a greenfield and massive opportunity. The way our technology works is by increasing genes twofold. That's where we live. And that positions us in a really good sweet spot for diseases that have a haploinsufficient nature, meaning one of the two alleles is no longer functional, and so essentially you have one functioning gene that gives you 50% of what you otherwise need to be healthy. So, that's how we think about the types of diseases that we go after. For our own purposes, we are building a pipeline of CNS haploinsufficient diseases, and that starts with SYNGAP1.
But the platform itself is broadly applicable to any tissue or any disease where you want to increase a gene. So, for example, we put in place a relationship with GSK to go after larger indications. This next year is a year of building, I think, execution. So, we are the first company to bring a disease-modifying approach into SYNGAP1, which I know we'll talk about more. So we're going to be making a lot of progress over the next year as we start dosing patients, as you correctly pointed out, and we've got into data in the first half of 2028. We've also just recently announced some new programs with SHANK3 as well, Phelan-McDermid syndrome behind that. So that'll be another thing that we're working on.
Thank you for that great overview. So maybe stepping back to the platform, can you walk us through how does it work? So how is it different from other genetic approaches? How do you identify target regulatory RNAs, and do you ensure selectivity for them, which is a critical part of, especially for genetic programs?
Yeah, absolutely. So, to start with, every protein-coding gene in our body has its own unique RNAs that control the expression. These are called regulatory RNAs. Now, what makes them very unique and special is that regulatory RNAs are specific to the protein-coding gene that they're acting on. So, every protein-coding gene has its own RNA. That RNA is not acting on many different genes. So you have built-in specificity at the genetic transcriptional level. We've chosen to use antisense oligonucleotides to drug those regulatory RNAs to maintain that specificity, because ASOs are specific as well due to the nature of their chemistry, which is RNA binding. So, we preserve that specificity for the reason you're acting, because we agree specificity is important.
What makes us really unique is that we are acting at the transcriptional level, meaning we're essentially turning the faucet on more, right at the source of the problem. Other approaches are either packaging some type of RNA or protein and delivering it, like an AAV approach, or they're acting further downstream. They're trying to essentially change things at the RNA level, if you will. We can talk more about the advantages and disadvantages of that.
Yeah, maybe following up on that point. As you were mentioning at the beginning, a key feature of your program is the ability to regulate, to increase expression up to two-fold.
How do you ensure that is enough, first of all, and considering the type of disorders you are targeting? Also, how do you ensure that you don't overshoot expression, which is always a risk when you modulate gene expression?
Yep. We have learned, because we've been doing this for so long now, that we actually never get above a two-fold increase. There's some biological reason for that, but we think that's a feature of the system, right? Because you're certainly correct that there's many diseases where overexpression would be a problem. We don't believe we have that problem just based on the biology and what we've seen so far. To turn that around, then you would ask, "Well, where is that most relevant?" As I mentioned earlier, any disease that has a loss of protein in it, if you will, is a really good place for us to start. Now, we like single-gene diseases, because those are easy to understand, if you will. It's very clear what the culprit is that's causing the disease.
Interestingly, in many of these cases, human genetics can give us a clue as to how much upregulation you actually need. In the case of SYNGAP1, probably 95%-98% of the population is haploinsufficient, meaning they only have 50% protein expression. However, there are a very small subsegment of patients that are, say, 1%-2%, they have a milder mutation that gives them about 75% instead of 50%, okay? You are halfway to being fully normal. We know that these patients are milder. They can respond to some medications. They can go to certain types of schools. Mother Nature has essentially told us that if you start to put more SYNGAP1 back into the system, it is essentially a gradient, and you are going to create a healthier way to live for patients.
Makes sense. Maybe digging more into that indication. SYNGAP1, your first clinical program, that is a very severe disorder. It is characterized by both seizures, neurobehavioral delay, problems with cognition. Maybe, what is first of all, from an epidemiological point of view, what is the target population there, and how should we think about the difficulties in diagnosing, and how is the diagnostic rate changing over time?
Yep. This is one of those rare diseases that I believe will become very important moving forward. Every three to five years, a new rare disease shows up and people start with, "I have not heard of that," and then it becomes a household name, if you will, which is a good thing for the patient organizations. SYNGAP1, I believe, will be like that. This is a disease that was discovered about 15 years ago, right? It is a single gene disease, meaning one of your two alleles is no longer functional. It has an ICD-10 code. It has a natural history study. This is all thanks to a very well-organized and powerful patient advocacy group. Really, that is, I think, the most important thing about these rare diseases. It used to be in this type of disease that you went on an odyssey.
You would have a kid, a child that had it, they did not quite know what was going on. Now, thanks to, one, just awareness, but two, whole genome screening as well as genetic panels, typically what happens is these children miss their milestones or they have seizures by the age of two or three, and they are immediately referred to what I just said, and they get diagnosed. Diagnostics went from a 10-year odyssey down to one year, right? I think that is really great. It is still massively underdiagnosed. Why is that? Well, it is just the case in rare diseases. Before you really have an approved treatment, there is sort of a lag in diagnosis. But we are very confident that there are at least 10,000, if not more, patients in the U.S. I think that has been well validated by KOLs, by secondary research.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
